Guardion Health Sciences Inc

Guardion Health Sciences, Inc.is a clinical nutrition and diagnostics company, which develops medical foods and medical devices in the ocular health space and develops nutraceutical products to provide supportive health benefits to consumers. The company was founded by Michael Favish in 2009 and is headquartered in Houston, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardion Health Sciences, Inc. engages in the development and distribution of clinically supported dietary supplements and medical foods. The firm also offers science-based products and devices designed to support healthcare professionals, providers, patients, and consumers. The company was founded by Michael Favish in December 2009 and is headquartered in Houston, TX.

HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the “Effective Date”). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the “Plan”) approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024.

Guardion Health Sciences Announces Filing of Certificate of Dissolution

HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024.

Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock

Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments.

Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024

HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that today it closed on its Definitive Agreement to sell its Viactiv business to Doctor's Best Inc. for gross cash consideration of $17,200,000. The Company received net cash proceeds of $16,250,000 at closing, with another $225,000 retained in a third-party escrow account with U.S. Bank, NA, to be released in accordance with the terms of the transaction documents.

Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution

Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution

Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business

-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special Meeting of Stockholders on May 23, 2024 Board of Directors Urges Stockholders to Vote to Approve the Sale of the Company's Viactiv Brand and Business and Plan of Liquidation and Dissolution If both proposals are approved, stockholders would receive one or more liquidating cash distributions, which combined are expected to represent a premium over our recent stock price HOUSTON, TEXAS, May 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months ended March 31, 2024, as described below. The Company is also providing an update regarding proposals to be considered at its upcoming Special Meeting of Stockholders.

Guardion Health Sciences Announces

Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023

Guardion Health Sciences (NASDAQ: GHSI ) stock is rocketing higher on Wednesday after the company announced an agreement to sell its Activ Nutritional subsidiary. Doctor's Best is acting as the buyer of Activ Nutritional and that includes the Viactiv brand and business.

Why Is Guardion Health (GHSI) Stock Up 66% Today?

Guardion Health Sciences Inc (NASDAQ: GHSI) is up nearly 100% this morning after Doctor's Best Inc agreed to buy its Activ Nutritional LLC. Could Guardion Health stock climb any further?

What made Guardion Health stock double on Wednesday?

HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell its Activ Nutritional, LLC subsidiary, which owns the Viactiv® brand and business, to Doctor's Best Inc. (“Doctor's Best”), a wholly-owned subsidiary of Kingdomway USA Corp. (“Kingdomway”), for gross cash consideration of $17.2 million, payable in full at closing. The transaction has been approved by the respective Boards of Directors of Guardion and of Doctor's Best, and remains subject to normal and customary closing conditions, including approval of the transaction by the Company's stockholders at a forthcoming Special Meeting of Stockholders. Assuming requisite approval by the Company's stockholders, the transaction is expected to close during the quarter ending June 30, 2024.

Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor's Best Inc.

Viactiv ® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022

Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023

Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstrates Positive Results of Company's Focus on eCommerce Initiatives Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstrates Positive Results of Company's Focus on eCommerce Initiatives

Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023

Former President and Chief Executive Officer Bret Scholtes Resigning to Pursue Other Business Opportunities Former President and Chief Executive Officer Bret Scholtes Resigning to Pursue Other Business Opportunities

Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer

Viactiv® Product Line Total Revenue Increased approximately 37% for the Quarter Ended March 31, 2023 as compared to the Quarter Ended March 31, 2022 Viactiv® Product Line Total Revenue Increased approximately 37% for the Quarter Ended March 31, 2023 as compared to the Quarter Ended March 31, 2022

Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023

Viactiv® Product Line Generated Net Revenues of approximately $10.6 Million or 96% of Net Revenues for the Year Ended December 31, 2022 Viactiv® Product Line Generated Net Revenues of approximately $10.6 Million or 96% of Net Revenues for the Year Ended December 31, 2022

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022

HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.

Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements

HOUSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on January 6, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on January 9, 2023, the Company's common stock will trade on a post-split basis under the same symbol GHSI. The reverse stock split was approved by the Company's stockholders at the special meeting of stockholders held on January 5, 2023, with the final ratio determined by the Company's Board of Directors.

Guardion Health Sciences, Inc. Announces 1-for-50 Reverse Stock Split Effective on Pre-Market Opening on January 9, 2023

Solo Brands

Hall of Fame Resort & Entertainment

Microvast Holdings

Senseonics Holdings

Seanergy Maritime Hlds

XWELL Inc

This article focuses on penny stocks with “buy” ratings from analysts. Analysts have access to information about  companies that retail investors cannot obtain.

7 Penny Stocks That Actually Have Buy Ratings

HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 495,000 shares of Series C convertible redeemable preferred stock and 5,000 shares of Series D non-convertible redeemable preferred stock. Each share of Series C and Series D preferred stock has a purchase price of $9.50 per share, reflecting an original issue discount of 5% of the $10.00 stated value of each share. Each share of Series C preferred stock is convertible into shares of the Company's common stock at an initial conversion price of $0.15768 per share (which is equal to the average closing price of the Company's common stock for the five (5) trading days ended on November 28, 2022). Shares of the Series C preferred stock are convertible at the option of the holder at any time, conditioned upon and subsequent to receipt by the Company of stockholder approval for a reverse split of its common stock. The Company and the holders of the Series C preferred stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series C preferred stock, if and when converted. Total gross proceeds from the preferred stock offerings, before deducting discounts, placement agent's fees and other estimated offering costs and expenses, are estimated to be approximately $4.75 million.

Guardion Health Sciences Announces Pricing of Aggregate $4.75 Million Institutional Private Placement of Series C and Series D Redeemable Preferred Stock

Viactiv® Generated Net Revenues of Approximately $2.6 Million or 96% of Net Revenues for the Quarter Ended September 30, 2022

Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2022

New Viactiv Omega Boost™ Gel Bites Clinically Proven to Increase Omega-3 Levels by 51% in Just 4 Weeks

Guardion Health Sciences Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks

Viactiv® Product Line Contributes to Highest Quarterly Revenue in Company History of Approximately $3.275 Million, Shows Significant Revenue Growth from Prior Quarter Viactiv® Product Line Contributes to Highest Quarterly Revenue in Company History of Approximately $3.275 Million, Shows Significant Revenue Growth from Prior Quarter

Guardion Health Sciences Announces Financial Results for the Quarter Ended June 30, 2022

HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) announced that independent proxy advisory firm ISS recommends that Guardion stockholders vote in favor of proposal 3 and proposal 4 at the Company's upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on June 16, 2022. Only stockholders of record on the record date of April 18, 2022 are eligible to attend and vote on proposals presented at the Annual Meeting.

ISS Recommends Guardion Stockholders Vote for the Increase in Shares for Equity Plan and for the Reverse Stock Split at Guardion's Upcoming 2022 Annual Stockholders' Meeting

Cinedigm

Ideanomics Inc

McEwen Mining

Romeo Power

These seven undervalued penny stocks each have the potential to pay off for investors down later down the road. The post 7 Undervalued Penny Stocks to Buy for Massive Gains appeared first on InvestorPlace.

7 Undervalued Penny Stocks to Buy for Massive Gains

HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced an agreement with OmegaQuant Laboratories (“OmegaQuant”) to provide Guardion with analytic testing and laboratory support services for current and future products. Guardion is a clinical nutrition company that offers a portfolio of science-based, clinically-developed products that are designed to support the health needs of consumers, healthcare professionals and providers and their patients.

News for Guardion Health Sciences Inc Stock (GHSI)